AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17574481 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic gum group (Group A)
Number of subjects: 80
Study 17574481 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum group (Group B)
Number of subjects: 80
Study 17574481 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic + xylitol gum group (Group C)
Number of subjects: 80
Study 17574481 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum group (Group D)
Number of subjects: 80
Study 14959808 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized sodium cromoglycate (SCG)
Number of subjects: 0
Study 11845604 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine (with possible addition of enalapril and hydrochlorothiazide)
Number of subjects: 4695
Study 11845604 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with nitrendipine
Number of subjects: 4695
Study 11845604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4695
Study 11767208 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) 20 g per day for 4 weeks
Number of subjects: 26
Study 11767208 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 26
Study 11767208 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) 20 g per day with vitamin E 200 mg per day for 3 weeks
Number of subjects: 26
Study 11767208 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI) 20 g per day for 3 weeks
Number of subjects: 26
Study 9284857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bumetanide 3.25 mg at 0 hours and again at 6 hours
Number of subjects: 8
Study 9284857 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of bumetanide 0.5 mg/hr for 6 hours
Number of subjects: 8
Study 9284857 — intervention group
Group type: COMPARATOR
Intervention: Loading dose of 0.5 mg bumetanide at 0 hours followed by a bolus regimen
Number of subjects: 8
Study 8117360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-monounsaturated fat diet
Number of subjects: 15
Study 8117360 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet
Number of subjects: 15
Study 3101839 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone
Number of subjects: 35
Study 3101839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2199358 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydroergotoxine
Number of subjects: 80
Study 2199358 — intervention group
Group type: COMPARATOR
Intervention: Ginkgo biloba extract
Number of subjects: 80
Study 31957130 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT) session before procedure
Number of subjects: 159
Study 31957130 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Music Therapy)
Number of subjects: 159
Study 29999194 — intervention group
Group type: EXPERIMENTAL
Intervention: Muffins with 20 g flaxseed
Number of subjects: 0
Study 29999194 — intervention group
Group type: EXPERIMENTAL
Intervention: Muffins with 30 g flaxseed
Number of subjects: 0
Study 29999194 — intervention group
Group type: COMPARATOR
Intervention: Muffins with 0 g flaxseed
Number of subjects: 0
Study 29999194 — intervention group
Group type: EXPERIMENTAL
Intervention: Muffins with flax at any level
Number of subjects: 0
Study 29999194 — intervention group
Group type: EXPERIMENTAL
Intervention: Muffins stored at -20 °C for 6 months
Number of subjects: 0
Study 28327983 — intervention group
Group type: EXPERIMENTAL
Intervention: Coil embolization with adjunctive techniques (e.g., balloon remodeling)
Number of subjects: 132
Study 28327983 — intervention group
Group type: COMPARATOR
Intervention: Coil embolization
Number of subjects: 132
Study 26512849 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior oblique muscle recession
Number of subjects: 13
Study 23611095 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive positive fluid balance strategy
Number of subjects: 60
Study 23611095 — intervention group
Group type: COMPARATOR
Intervention: Non-restrictive positive fluid balance strategy
Number of subjects: 60
Study 21175801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric infusion of 300 mL of 0.1 mol/L hydrochloric acid
Number of subjects: 6
Study 21175801 — intervention group
Group type: COMPARATOR
Intervention: Water infusion (control)
Number of subjects: 6
Study 21175801 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric infusion of 0.1 mol/L hydrochloric acid
Number of subjects: 6
Study 19236410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupine-enriched pasta
Number of subjects: 12
Study 19236410 — intervention group
Group type: COMPARATOR
Intervention: Placebo pasta
Number of subjects: 12
Study 17485422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy at 8 mg/kg intravenously every 4 weeks
Number of subjects: 306
Study 17485422 — intervention group
Group type: COMPARATOR
Intervention: Conventional disease-modifying antirheumatic drugs (DMARDs)
Number of subjects: 306
Study 17485422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab monotherapy
Number of subjects: 306
Study 17485422 — intervention group
Group type: COMPARATOR
Intervention: DMARDs
Number of subjects: 306
Study 15152293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (4 mg/h continuously from admission to 48 h after PTCA)
Number of subjects: 83
Study 15152293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nicorandil treatment)
Number of subjects: 83
Study 15152293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil
Number of subjects: 83
Study 15152293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study 12466679 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.1 mg every 6 h, with one dose on-site each day and others taken home)
Number of subjects: 124
Study 12466679 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg IM daily)
Number of subjects: 124
Study 9433338 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed haloperidol doses intended to achieve plasma levels of 8‐18 ng/ml
Number of subjects: 66
Study 9433338 — intervention group
Group type: COMPARATOR
Intervention: Fixed haloperidol doses intended to achieve plasma levels of 25‐35 ng/ml
Number of subjects: 66
Study 9433338 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose reassignment for patients whose BPRS scores failed to improve by 30%
Number of subjects: 66
Study 9433338 — intervention group
Group type: COMPARATOR
Intervention: Higher dose reassignment for patients whose BPRS scores failed to improve by 30%
Number of subjects: 66
Study 7655699 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 40
Study 7655699 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 40
Study 7655699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2560555 — intervention group
Group type: EXPERIMENTAL
Intervention: RU 486 (glucocorticoid antagonist)
Number of subjects: 0
Study 2560555 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (healthy volunteers)
Number of subjects: 0
Study 2560555 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with major depression
Number of subjects: 0
Study 794895 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 78
Study 794895 — intervention group
Group type: EXPERIMENTAL
Intervention: dextroamphetamine
Number of subjects: 78
Study 794895 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 78
Study 31798985 — intervention group
Group type: EXPERIMENTAL
Intervention: EmOC&NC training
Number of subjects: 127
Study 27993387 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (SIMVA) 20 mg/d
Number of subjects: 120
Study 27993387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24852756 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptides isolated from pork skin (PCP)
Number of subjects: 0
Study 24852756 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen peptides isolated from bovine bone (BCP)
Number of subjects: 0
Study 24852756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23635625 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum hCG follow-up
Number of subjects: 376
Study 23635625 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound follow-up
Number of subjects: 376
Study 20617886 — intervention group
Group type: EXPERIMENTAL
Intervention: High performers (young and old)
Number of subjects: 0
Study 20617886 — intervention group
Group type: COMPARATOR
Intervention: Low performers (young and old)
Number of subjects: 0
Study 20617886 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study 19122553 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with isobaric bupivacaine 0.5% and 5 microg sufentanil intrathecally
Number of subjects: 132
Study 19122553 — intervention group
Group type: COMPARATOR
Intervention: Epidural anaesthesia with ropivacaine 0.75% and 10 microg sufentanil epidurally
Number of subjects: 132
Study 17545717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir 1400/200 mg once a day plus TDF 300 mg once a day
Number of subjects: 30
Study 17545717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosamprenavir/ritonavir 1400/100 mg once a day plus TDF 300 mg once a day
Number of subjects: 30
Study 14722034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus paclitaxel (two dose levels)
Number of subjects: 53
Study 14722034 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus fluorouracil
Number of subjects: 53
Study 14722034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 53
Study 11468730 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial daily induction with 10 million units (MU) IFNalpha‐n1, s.c., for 13 months followed by intermittent therapy (group 1, n = 50)
Number of subjects: 155
Study 11468730 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IFNalpha‐n1 therapy with initial daily induction (group 2, n = 52)
Number of subjects: 155
Study 11468730 — intervention group
Group type: COMPARATOR
Intervention: Standard IFNalpha‐n1 therapy (group 3, n = 53)
Number of subjects: 155
Study 11468730 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial daily induction with 10 MU IFNalpha‐n1 (group 1)
Number of subjects: 155
Study 11468730 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IFNalpha‐n1 therapy (group 2)
Number of subjects: 155
Study 11468730 — intervention group
Group type: COMPARATOR
Intervention: Standard IFNalpha‐n1 therapy (group 3)
Number of subjects: 155
Study 11468730 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy (group 1)
Number of subjects: 155
Study 11468730 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily high‐dose treatment
Number of subjects: 155
Study 9875905 — intervention group
Group type: EXPERIMENTAL
Intervention: PAFra (120 mg iv every 12 hrs over a 4-day period)
Number of subjects: 609
Study 9875905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 609
Study 9875905 — intervention group
Group type: EXPERIMENTAL
Intervention: PAFra
Number of subjects: 609
Study 9875905 — intervention group
Group type: COMPARATOR
Intervention: PAFra and Placebo
Number of subjects: 609
Study 7986594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 81
Study 2647818 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with freeze-dried birch-pollen antigens for 18 months, cumulative dose of 280 x 10(6) biologic units
Number of subjects: 39
Study 2647818 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 39
Study 2647818 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 39
Study 30340895 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise protocol (50% Wmax)
Number of subjects: 15
Study 30340895 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous exercise at 70% Wmax in dehydrated state
Number of subjects: 15
Study 30340895 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous dehydrated protocol
Number of subjects: 15
Study 30340895 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise at 70% Wmax in hydrated condition
Number of subjects: 15
Study 30340895 — intervention group
Group type: COMPARATOR
Intervention: Rest protocol
Number of subjects: 15
Study 27670203 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine plus prednisolone (single dose followed by two of placebo for 7 days)
Number of subjects: 210
Study 27670203 — intervention group
Group type: COMPARATOR
Intervention: Dexchlorpheniramine plus betamethasone (three daily doses for 7 days)
Number of subjects: 210
Study 26305866 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAID use
Number of subjects: 4726
Study 26305866 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 4726
Study 26305866 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis
Number of subjects: 4726
Study 26305866 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic musculoskeletal pain
Number of subjects: 4726
Study 26305866 — intervention group
Group type: EXPERIMENTAL
Intervention: General musculoskeletal complaints
Number of subjects: 4726
Study 26305866 — intervention group
Group type: EXPERIMENTAL
Intervention: Headaches
Number of subjects: 4726
Study 26305866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatica
Number of subjects: 4726
Study 26305866 — intervention group
Group type: EXPERIMENTAL
Intervention: Atherosclerotic disease
Number of subjects: 4726
Study 23864517 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation-based meta-cognitive strategy-training program
Number of subjects: 19
Study 23864517 — intervention group
Group type: COMPARATOR
Intervention: Education about brain health and cognitively stimulating exercises
Number of subjects: 19
Study 21640518 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation therapy with chemotherapy (RT-CHT)
Number of subjects: 600
Study 21640518 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiation therapy alone (RT)
Number of subjects: 600
Study 21640518 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall group (RT-CHT and RT)
Number of subjects: 600
Study 19410064 — intervention group
Group type: EXPERIMENTAL
Intervention: NA Internal
Number of subjects: 177
Study 19410064 — intervention group
Group type: EXPERIMENTAL
Intervention: NA External
Number of subjects: 177
Study 19410064 — intervention group
Group type: COMPARATOR
Intervention: NR
Number of subjects: 177
Study 17632307 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergeyes lenses
Number of subjects: 50
Study 17632307 — intervention group
Group type: COMPARATOR
Intervention: Soflens 66 Toric lenses
Number of subjects: 50
Study 15343163 — intervention group
Group type: EXPERIMENTAL
Intervention: NiCr alloy, vacuum casting (VVC)
Number of subjects: 40
Study 15343163 — intervention group
Group type: EXPERIMENTAL
Intervention: CoCr alloy, vacuum casting (WVC)
Number of subjects: 40
Study 15343163 — intervention group
Group type: COMPARATOR
Intervention: NiCr alloy, acetylene‐oxygen flame casting (VFC)
Number of subjects: 40
Study 15343163 — intervention group
Group type: COMPARATOR
Intervention: CoCr alloy, acetylene‐oxygen flame casting (WFC)
Number of subjects: 40
Study 15343163 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially pure Ti alloy (Ti)
Number of subjects: 40
Study 15343163 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (VVC, WVC, VFC, WFC)
Number of subjects: 40
Study 11403243 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programming (Study group, n = 11)
Number of subjects: 21
Study 11403243 — intervention group
Group type: COMPARATOR
Intervention: Traditional outpatient therapy (Home group, n = 10)
Number of subjects: 21
Study 9743818 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS 4&6, 3 x 400 mg/day)
Number of subjects: 119
Study 9743818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 8036825 — intervention group
Group type: EXPERIMENTAL
Intervention: PDEV vaccine
Number of subjects: 2
Study 8036825 — intervention group
Group type: EXPERIMENTAL
Intervention: HDCV vaccine
Number of subjects: 2
Study 8036825 — intervention group
Group type: COMPARATOR
Intervention: Control group (subjects aged 11-25 years)
Number of subjects: 2
Study 8036825 — intervention group
Group type: EXPERIMENTAL
Intervention: PDEV and HDCV vaccines
Number of subjects: 2
Study 2656601 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride rinse
Number of subjects: 0
Study 2656601 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30910489 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonanimal hyaluronic acid (NASHA) 1 mL intra-articular injection
Number of subjects: 37
Study 28194823 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone viewing of CXR images
Number of subjects: 21
Study 28194823 — intervention group
Group type: COMPARATOR
Intervention: Computer screen viewing of CXR images
Number of subjects: 21
Study 25171195 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 201
Study 25171195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 23609383 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine plus sertraline
Number of subjects: 259
Study 23609383 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine plus placebo
Number of subjects: 259
Study 20511127 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive training incorporated into the regular training regimen of the training group.
Number of subjects: 20
Study 20511127 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy athletes of other sports).
Number of subjects: 20
Study 18422164 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal spray < or =400 microg/d
Number of subjects: 36
Study 18422164 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal spray 1 ‐ <3 year
Number of subjects: 36
Study 18422164 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal spray 3 ‐ <5 year
Number of subjects: 36
Study 18422164 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) nasal spray > or =5 year
Number of subjects: 36
Study 15926303 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) at 2.5 ATA
Number of subjects: 23
Study 12651647 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 240
Study 12651647 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 240
Study 12651647 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 2 g
Number of subjects: 240
Study 12651647 — intervention group
Group type: COMPARATOR
Intervention: Control (Vitamin C 500 mg)
Number of subjects: 240
Study 11185633 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 12
Study 11185633 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg plus Telmisartan 120 mg
Number of subjects: 12
Study 8858323 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-induced fluorescence spectroscopy
Number of subjects: 0
Study 8348256 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5 mg for children younger than one year and 1 mg for older children)
Number of subjects: 107
Study 8348256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 3538106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 microgram/kg body weight)
Number of subjects: 20
Study 3538106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study 3538106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide
Number of subjects: 20
Study 3538106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29526139 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal-flow pump
Number of subjects: 366
Study 29526139 — intervention group
Group type: COMPARATOR
Intervention: Axial-flow pump
Number of subjects: 366
Study 24768240 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed FP7 Glaucoma Valve (AGV)
Number of subjects: 276
Study 24768240 — intervention group
Group type: COMPARATOR
Intervention: Baerveldt Glaucoma Implant (BGI)
Number of subjects: 276
Study 22500700 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rMS
Number of subjects: 34
Study 22500700 — intervention group
Group type: COMPARATOR
Intervention: Sham rMS
Number of subjects: 34
Study 19740120 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1000 mg
Number of subjects: 0
Study 19740120 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 0
Study 19740120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18633764 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 32
Study 18633764 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 32
Study 18633764 — intervention group
Group type: COMPARATOR
Intervention: Control (wash-out period)
Number of subjects: 32
Study 15719703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus II microparticle enzyme immunoassay (MEIA)
Number of subjects: 1121
Study 12121486 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg by mouth)
Number of subjects: 0
Study 12121486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12121486 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (50 microg/day)
Number of subjects: 0
Study 11829851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary operation (group I)
Number of subjects: 172
Study 11829851 — intervention group
Group type: COMPARATOR
Intervention: Operation after ligation of drained vessels (group II)
Number of subjects: 172
Study 7883844 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 180
Study 7883844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 7883844 — intervention group
Group type: EXPERIMENTAL
Intervention: CrossLaps ELISA baseline values
Number of subjects: 180